Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
The two main incretins involved in this process are glucagon-like peptide-1 (GLP-1 ... there are two approved GLP-1 and one combined GIP/ GLP-1 receptor agonists indicated for chronic weight ...
As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
Glucagon-like peptide-1 receptor agonist medications for weight loss are significantly transforming the field of facial plastic surgery.
is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, tirzepatide, liraglutide, dulaglutide ...
HealthDay on MSN11d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of TreatmentThe absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.
Both SLGT2 inhibitors and GLP-1s lowered moderate or severe ... Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback